Exp Dermatol:帕霉素可通过ERK1/2和mTOR通路调节原肌球蛋白的表达和甲基化水平来改善银屑病

2018-09-22 MedSci MedSci原创

牛皮癣是一种慢性炎症性疾病,影响着全世界数百万人。最近,据报道mTOR抑制剂雷帕霉素(RAPA)参与牛皮癣的发病机理,但是其潜在的机制仍不清楚。 苏木精和伊红染色用于检查RAPA对银屑病患者和动物模型患者的损伤组织的炎症水平的影响。实时定量PCR,免疫组织化学和蛋白质印迹分析用于评估RAPA对牛皮癣患者,细胞模型和动物模型中原肌球蛋白(TPM)表达的影响。鬼笔环肽染色用于评估RAPA对细胞骨

牛皮癣是一种慢性炎症性疾病,影响着全世界数百万人。最近,据报道mTOR抑制剂雷帕霉素(RAPA)参与牛皮癣的发病机理,但是其潜在的机制仍不清楚。

苏木精和伊红染色用于检查RAPA对银屑病患者和动物模型患者的损伤组织的炎症水平的影响。实时定量PCR,免疫组织化学和蛋白质印迹分析用于评估RAPA对牛皮癣患者,细胞模型和动物模型中原肌球蛋白(TPM)表达的影响。鬼笔环肽染色用于评估RAPA对细胞骨架的影响。通过CCK-8测定,EdU染色和流式细胞术检测RAPA对细胞增殖和细胞周期的影响。通过甲基化特异性PCR分析TPM的甲基化状态。

结果显示,TPM1和TPM2的表达明显下调,而其病理组织,细胞模型和银屑病动物模型的甲基化水平明显较高。RAPA处理后,牛皮癣的细胞模型和动物模型中TPM的表达和甲基化水平均得到恢复。RAPA抑制银屑病的Hacat或人表皮角质形成细胞模型中的细胞增殖并降低S期细胞的比例。最后,RAPA的处理抑制了牛皮癣细胞模型和动物模型中激活的ERK1/2和mTOR通路。

因此,通过抑制ERK1/2和mTOR信号传导通路降低TPM1和TPM2的甲基化水平,RAPA可用作治疗牛皮癣的有效药物。

原始出处:

Gao M, Si X. Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of Tropomyosin via ERK1/2 and mTOR pathways in vitro and in vivo. Exp Dermatol. 2018 Jul 17. doi: 10.1111/exd.13745.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752113, encodeId=fc211e5211317, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Jun 10 21:57:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720775, encodeId=e7271e2077565, content=<a href='/topic/show?id=991e69e82ba' target=_blank style='color:#2F92EE;'>#甲基化水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69782, encryptionId=991e69e82ba, topicName=甲基化水平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86f732973339, createdName=sunyl18, createdTime=Mon Feb 25 07:57:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035175, encodeId=81d120351e551, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Jan 09 05:57:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-06-10 chenlianhui
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752113, encodeId=fc211e5211317, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Jun 10 21:57:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720775, encodeId=e7271e2077565, content=<a href='/topic/show?id=991e69e82ba' target=_blank style='color:#2F92EE;'>#甲基化水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69782, encryptionId=991e69e82ba, topicName=甲基化水平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86f732973339, createdName=sunyl18, createdTime=Mon Feb 25 07:57:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035175, encodeId=81d120351e551, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Jan 09 05:57:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752113, encodeId=fc211e5211317, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Jun 10 21:57:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720775, encodeId=e7271e2077565, content=<a href='/topic/show?id=991e69e82ba' target=_blank style='color:#2F92EE;'>#甲基化水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69782, encryptionId=991e69e82ba, topicName=甲基化水平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86f732973339, createdName=sunyl18, createdTime=Mon Feb 25 07:57:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035175, encodeId=81d120351e551, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Jan 09 05:57:00 CST 2019, time=2019-01-09, status=1, ipAttribution=)]
    2019-01-09 xzw113